A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Checked against the public recordLast updated Jul 20, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: BMS-986463
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. * Participants must have an unresectable/metastatic carcinoma. Exclusion Criteria * Participants must not have Leptomeningeal metastases. * Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment. * Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment. * Other protocol-defined Inclusion/Exclusion criteria apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- Valkyrie Clinical TrialsLos Angeles, California
- John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey
- Local Institution - 0045Columbus, Ohio
- Local Institution - 0046Dallas, Texas
- Local Institution - 0049Houston, Texas
- BC Cancer VancouverVancouver, British Columbia
- Princess Margaret Cancer CentreToronto, Ontario
- Centre Hospitalier de l'Université de MontréalMontreal, Quebec
- Jewish General HospitalMontreal, Quebec
- Local Institution - 0036Bordeaux, Aquitaine
- Local Institution - 0031Villejuif, Val-de-Marne
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 20, 2026. Always confirm current availability with the study team.